Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Preclinical CRO Market 

5.1. COVID-19 Landscape: Preclinical CRO Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Preclinical CRO Market, By Service

8.1. Preclinical CRO Market, by Service Type, 2023-2032

8.1.1. Toxicology Testing

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Bioanalysis & DMPK Studies

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Chemistry

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Compound Management

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Safety Pharmacology

8.1.5.1. Market Revenue and Forecast (2020-2032)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Preclinical CRO Market, By End Use

9.1. Preclinical CRO Market, by End Use, 2023-2032

9.1.1. Medical Device Companies

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Biopharmaceutical

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Government & Academic Institutes

9.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Preclinical CRO Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Service (2020-2032)

10.1.2. Market Revenue and Forecast, by End Use (2020-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.1.3.2. Market Revenue and Forecast, by End Use (2020-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.1.4.2. Market Revenue and Forecast, by End Use (2020-2032)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.2. Market Revenue and Forecast, by End Use (2020-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.3.2. Market Revenue and Forecast, by End Use (2020-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.4.2. Market Revenue and Forecast, by End Use (2020-2032)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.5.2. Market Revenue and Forecast, by End Use (2020-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.6.2. Market Revenue and Forecast, by End Use (2020-2032)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.2. Market Revenue and Forecast, by End Use (2020-2032)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.3.2. Market Revenue and Forecast, by End Use (2020-2032)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.4.2. Market Revenue and Forecast, by End Use (2020-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.5.2. Market Revenue and Forecast, by End Use (2020-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.6.2. Market Revenue and Forecast, by End Use (2020-2032)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.2. Market Revenue and Forecast, by End Use (2020-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.3.2. Market Revenue and Forecast, by End Use (2020-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.4.2. Market Revenue and Forecast, by End Use (2020-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.5.2. Market Revenue and Forecast, by End Use (2020-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.6.2. Market Revenue and Forecast, by End Use (2020-2032)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Service (2020-2032)

10.5.2. Market Revenue and Forecast, by End Use (2020-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.5.3.2. Market Revenue and Forecast, by End Use (2020-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.5.4.2. Market Revenue and Forecast, by End Use (2020-2032)

Chapter 11. Company Profiles

11.1. Wuxi AppTec

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Pharmaceutical Product Development

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Medpace, Inc.

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Charles River Laboratories International, Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. PRA Health Science, Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. PAREXEL

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Envigo

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Eurofins Scientific.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Laboratory Corporation of America

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. ICON Plc

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms